U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23FN2O2
Molecular Weight 366.4286
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROLUPERIDONE

SMILES

FC1=CC=C(C=C1)C(=O)CN2CCC(CN3CC4=C(C=CC=C4)C3=O)CC2

InChI

InChIKey=RNRYULFRLCBRQS-UHFFFAOYSA-N
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2

HIDE SMILES / InChI

Molecular Formula C22H23FN2O2
Molecular Weight 366.4286
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.53 nM [Ki]
Target ID: Q5BJF2
Gene ID: 27346.0
Gene Symbol: TMEM97
Target Organism: Homo sapiens (Human)
8.19 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group.
After at least 5 days' withdrawal from all antipsychotic medication, Schizophrenia patients were randomly assigned to receive 32 mg/day or 64 mg/day of oral CYR-101 (MIN-101) for 12 weeks.
Route of Administration: Oral
CYR-101 (MIN-101) has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively).
Substance Class Chemical
Created
by admin
on Thu Jul 06 12:40:20 UTC 2023
Edited
by admin
on Thu Jul 06 12:40:20 UTC 2023
Record UNII
4P31I0M3BF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROLUPERIDONE
USAN   INN  
Official Name English
MIN-101 FREE BASE
Code English
ROLUPERIDONE [USAN]
Common Name English
2-({1-[2-(4-Fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2,3-dihydro-1H-isoindol-1-one
Systematic Name English
FMI
Code English
CYR-101
Code English
roluperidone [INN]
Common Name English
1H-ISOINDOL-1-ONE, 2-((1-(2-(4-FLUOROPHENYL)-2-OXOETHYL)-4-PIPERIDINYL)METHYL)-2,3-DIHYDRO-
Systematic Name English
Code System Code Type Description
WIKIPEDIA
CYR-101
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
EPA CompTox
DTXSID10189512
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
USAN
EF-67
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
FDA UNII
4P31I0M3BF
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
PUBCHEM
9799284
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
DRUG BANK
DB13080
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
CAS
359625-79-9
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
INN
10810
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
SMS_ID
100000183602
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
NCI_THESAURUS
C166772
Created by admin on Thu Jul 06 12:40:21 UTC 2023 , Edited by admin on Thu Jul 06 12:40:21 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY